{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
chlorphenesin carbamate
to a specific field?
Status:
US Previously Marketed
Source:
DAKLINZA by BRISTOL-MYERS SQUIBB
(2015)
Source URL:
First approved in 2015
Source:
DAKLINZA by BRISTOL-MYERS SQUIBB
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Daclatasvir (BMS-790052) is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 3 infection. Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.
Status:
US Previously Marketed
Source:
ZONTIVITY by KEY THERAP
(2014)
Source URL:
First approved in 2014
Source:
ZONTIVITY by KEY THERAP
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Vorapaxar is a tricyclic himbacine-derived oral thrombin receptor antagonist that acts by reversible inhibition of the protease-activated receptor-1 (PAR-1). PAR-1 is expressed on platelets and its inhibition prevents platelets from aggregation. Vorapaxar is approved by FDA and is indicated for the reduction of recurring thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. Vorapaxar at the same time may cause bleeding complications including intracranial haemorrhage (ICH), when compared to standard therapy alone. That is why Vorapaxar is contraindicated in patients with prior stroke, transient ischemic attack and ICH.
Status:
US Previously Marketed
Source:
ETHMOZINE by SHIRE
(1990)
Source URL:
First approved in 1990
Source:
ETHMOZINE by SHIRE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Moricizine is an antiarrhythmic agent previously marketed as Ethmozine. It was used for prophylaxis and treatment of serious and life-threatening ventricular arrhythmias. In 2007 it was withdrawn and discontinued for commercial reasons. Moricizine can be administered intravenously but was more commonly provided as an oral formulation.
Status:
US Previously Marketed
Source:
EMCYT by PHARMACIA AND UPJOHN
(1981)
Source URL:
First approved in 1981
Source:
EMCYT by PHARMACIA AND UPJOHN
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard moiety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.
Status:
First approved in 1965
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Tybamate is a minor tranquilizer that is chemically and pharmacologically related to meprobamate. It is useful in treating anxiety and tension associated with psychoneurotic disorders.
Status:
First approved in 1961
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
HYDROXYPHENAMATE (LISTICA®) is a carbamate tranquilizer indicated for anxiety. It resembles meprobamate in its effect.
Status:
US Previously Marketed
Source:
STRIATRAN by MSD
(1961)
Source URL:
First approved in 1960
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
EMYLCAMATE (STRIATRAN®), the carbamate ester of the tertiary alcohol methylpentanol, is a tranquilizing and muscle relaxant agent used for the treatment of anxiety and tension.
Status:
First approved in 1958
Class (Stereo):
CHEMICAL (RACEMIC)
Styramate is a nonsedative skeletal muscle relaxant drug, developed by the Armour Pharmaceutical Company in 1952. The drug induces relaxation of skeletal musculus by interruption of nerve transmission in the spinal cord and brain stem rather than by exerting a blocking effect at the junction between the motor nerves and the muscles. In mouse studies styramate was found to exert a selective antagonism to hindleg extensor tonic spasm, induced by maximal electroshock, pentylenetetrazol, and strychnine sulfate. In the clinic, the drug was used in patients with neurologic and neuromuscular disorders, secondary muscular spasms. Styramate is marketed in South Africa under tradename Sinaxamol.
Status:
US Previously Marketed
Source:
VALMID by DISTA
(1955)
Source URL:
First approved in 1955
Source:
VALMID by DISTA
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ethinamate was used to treat insomnia (trouble in sleeping) under the brand name VALMID, but then was replaced by other more efficacy medicines. The mechanism of action was not known. However, was studies, which showed that ethinamate inhibits carbonic anhydrases I and did not inhibit II. Nevertheless, even inhibition carbonic anhydrases I is not sufficiently strong to implicate carbonic anhydrases I in the mechanism of action.
